{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Eli Lilly & Co releases data showing its experimental Alzheimer's drug solanezumab may be effective in mild cases; Biogen releases mixed results from its drug aducanumab.", "type_of_material": "News", "word_count": "818", "lead_paragraph": "Solanezumab, from Eli Lilly, is getting another look for mild cases, and Biogen said data from a small group taking aducanumab showed mixed results.", "pub_date": "2015-07-23T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "New Data on 2 Alzheimer\u2019s Drugs Alters Hope and Expectation", "print_headline": "New Data on 2 Alzheimer&#8217;s Drugs Alter Hope and Expectation for Treatments"}, "snippet": "Solanezumab, from Eli Lilly, is getting another look for mild cases, and Biogen said data from a small group taking aducanumab showed mixed results.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/07/23/business/new-data-on-2-alzheimers-drugs-alters-hope-and-expectation.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Alzheimer's Disease", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Eli Lilly and Company", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Biogen Idec Inc", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Clinical Trials", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Alzheimer's Assn", "name": "organizations"}], "blog": [], "_id": "55af77b838f0d86d036e5307", "source": "The New York Times"}